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Abstract 
 
         Background:Fluoroquinolones  are  among  the  anti-microbial  that  have  widespread  use  for 
treatment of community- and hospital-acquired infections. Although uncommon, hypoglycemia has 
been reported with some fluoroquinolones and appears to occur most frequently in elderly patients 
with type 2 diabetes mellitus who were receiving therapy with oral hypoglycemics. The clinical data 
emerged  suggest  that  the  fluoroquinolones  can  affect  glucose  homeostasis  through  an  unknown 
mechanism. The present work aimed to explore the potential effects of some fluoroquinolones on 
glucose  metabolism  and  blood  glucose  level  in  experimental  animals.  Two  fluoroquinolones 
(gatifloxacin, moxifloxacin) were used in the present study using different rabbit groups;  normal 
and experimentally diabetic. Dug interaction with anti-diabetic drugs was also investigated. Safety 
considerations were our goal. 
         Materials  And  Method:  In    the  present    work,    alloxan  (100  mg  /  kg  body    weight    3 
successive doses, intraperitonially) was  used  to  induce  diabetes in  experimental animals.    The 
blood glucose level after alloxan was measured. Oral anti-diabetics glimepiride, rosiglitazone, and 
metformin  produced  significant  lowering  effect  on  blood  glucose  level  in  normal  and  diabetic 
animals. Gatifloxacin and moxifloxacin  were similar in producing lowering of blood glucose  level  
in  non  diabetic and diabetic  animals and significantly potentiated the  hypoglycemic  action  of  
oral anti-diabetics in  the alloxan diabetic  rabbits. 
         Keywords:  Oral  anti-diabetics  Glimepiride,  Rosiglitazone,  Metformin,  Fluoroquinolones 
(Gatifloxacin and Moxifloxacin) Alloxan and diabetes mellitus.   
 
Introduction 
 
         A  variety  of  medications  has  been 
associated with hypoglycemia, and the list of 
these  medications  is  expanding.  Fluoroqu-
inolones  are  generally  regarded  as  safe 
antimicrobial  agents  with  relatively  few 
adverse effects or drug interaction (Basaria et 
al., 2002). 
         The World Health Organization (WHO) 
recognized  type  2  diabetes  and  obesity  as  a 
global  health  problem  that  has  reached 
epidemic proportion (WHO, 1997).  Diabetes  
mellitus    is    one    of    the    most    common  
diseases in   the    world;   it   was    estimated  
that    150    million    patients  suffered    from  
diabetes    mellitus    in  the  year  2000  (Buse, 
2000),  and  that  number  may  reach  300 
millions  in  the  year  2025  (Zimmet,  2003). 
Many  drugs  produce  a  hypoglycemic  state  
in  normal and  diabetic  persons  by different 
mechanisms of action. Some of them are used 
mainly  for  this  therapeutic  effect  like 
sulfonylureas,  metformin  and  rosiglitazone 
(Harrower, 1996 , Buse, 2000, and Harrigan 
et al.,  2001).   Other    agents   intensify    the  
hypoglycemic  action of  oral  hypoglycemics  
such  as  chloramphenicol  (Brunova  et  al., 
1977),  tetracycline  (Basaria  et  al,  2002), 
erythromycin  (Petrakis  et  al.,  1999), 
clarithromycin  (Bussing  and  Gende,  2002), 
isoniazid (Ovali et al., 2004), and rifampicin 
(Niemi et al., 2001b).   
         Alloxan    hyperglycemic  effect  is    due  
to  partial  or  total  necrosis  of  beta  cells  
which    is    presented  histopathologically    by  
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degeneration    and    nuclear  pykinosis  
(Szkudelski et al., 1998).  Alloxan exerts its 
diabetogenic  action  when  it  is  administered 
parenterally: intravenously, intraperitoneal  or 
subcutaneously. The dose of alloxan required 
for  inducing  diabetes  depends  on  the  animal 
species,  route  of  administration  and 
nutritional  status  (Szkudelski,  2001).  When 
alloxan  is  given  intraperitonealy  or 
subcutaneously its effective dose must be 2-3 
times  higher  than  the  intravenous  dose.  An 
intraperitonial  dose  below  150  mg/kg body 
weight  may  be  insufficient  for  inducing 
diabetes. Fasted animals are more susceptible 
to alloxan, whereas, increased blood  glucose 
provides partial  protection  (Bansal  et  al., 
1980, Szkudelski et al., 1998). 
         Fluoroquinolones such as ciprofloxacin, 
levofloxacin,  moxifloxacin  and  gatifloxacin 
are widely used for the treatment of bacterial 
infections.  Fluoroquinolones-induced  adverse 
effects  have  been  reported  to  occur  with 
increased  frequency  in  the  elderly,  but  large 
trials  comparing  the  tolerability  in  aged  and 
young  individuals  are  still  not  available 
(Stallman  and  Lode,  2003).  Despite  their 
widespread  use  for  the  treatment  of 
community-  and  hospital-acquired  infections. 
Uncommon  hypoglycemia  has  been  reported 
with all  the fluoroquinolones  and appears  to 
occur most frequently in elderly patients with 
type  2  diabetes  mellitus  who  are  receiving 
therapy  with  oral  hypoglycemics.  The  exact 
mechanism of this effect is unknown, but it is 
postulated  to  be  a  result  of  blockage  of 
adenosine  5'-triphosphate-sensitive  potassium 
channels  in  pancreatic  beta-cell  membranes 
(Gavin et al., 2004, Friedrich and Dougherty, 
2004). It was reported that patients receiving 
oral  hypoglycemic  agents  are  at  greater  risk 
of  experiencing  gatifloxacin-induced 
hypoglycemia  than  patients  not  receiving 
these  agents.  Clinicians  should  be  aware  of 
this  potentially  life-threatening  adverse  event 
and  monitor  blood  glucose  levels  in  all 
patients  receiving  concomitant  oral 
hypoglycemic  agents  and  gatifloxacin 
(LeBlanc  and  Cossette,  2004).  Gatifloxacin-
induced  hypoglycemia  may  persist  for  24 
hours after stoppage of the drug (Baker and 
Hangii, 2002).  
         Glimepiride,  a  hypoglycemic  sulfonyl-
urea drug causes  reduction of blood  glucose 
level predominantly via stimulation of insulin 
release  from  pancreatic  β  cells.  In  addition, 
during  long-term  treatment,  an  insulin-
independent  blood  glucose  decreasing 
mechanism  is  assumed  to  operate  (Gunter 
Muller,  2000).  Mechanism  of  action  of 
metformin  is  uncertain  despite  its  known 
therapeutic  benefits.  Its  mode  of  action 
appears  to  involve  reduction  of  hepatic 
gluconeogenesis,  decreased  absorption  of 
glucose  from  the  gastrointestinal  tract,  and 
reduced  insulin  insensitivity  (Zhou  et  al., 
2001). Rosiglitazone is an anti-diabetic drug 
from  the  thiazolidinedione  class,  its  mecha-
nism  of  action  is  by  activation  of  the 
intracellular receptor class of the peroxisome 
proliferator-activated  receptors  (PPARs), 
specifically  PPARγ  receptors.  Rosiglitazone 
is  a  pure  ligand  of    PPARγ,  and  has  no 
PPARʱ- binding action. Apart from its effect 
on insulin resistance  , it appears  to have  an 
anti-inflammatory  effect.  (Mohandy  et  al., 
2004) 
 
Materials And Method 
 
A) MATERIALS 
 
I. Drugs and chemical agents 
1) Alloxan 
Alloxan monohydrate (B.D.H., England): It is 
freely soluble in water. 
2)  Fluoroquinolones  (gatifloxacin  and 
moxifloxacin) were  injected in  dose  of 
20,  40,  and  80  mg  /kg  body  weight 
(bw) /day /rabbit intraperitonially. 
3)  Oral  anti-diabetics  glimepiride  (1.3  mg/ 
Kg bw /day /rabbit), rosiglitazone (1.3 
mg /kg bw /day /rabbit), and metformin 
(160  mg  /Kg  bw  /day  /rabbit),  were 
administered  orally  in  different  doses 
daily. 
4)  Intermediate  acting  insulin  (Semilent 
insulin,  Novo)  injected  subcutaneously 
at a dose of 0.5 U / Kg bw. 
11)  Animals 
         Male mixed breed rabbits weighing 1.8 
- 2.5 Kg were used in this study, animal food 
(pellet)  and  water  were  freely  supplied. Amr Heshmat Rostom  & Ali Ibrahim Al-Sultan   
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Animals were divided into 8 groups each of 8 
rabbits. 
Group  1:    Served  as  control  to  study  blood 
glucose  level  of  control  non-treated 
rabbits and after giving alloxan     
Groups  2, 3, 4:  Served  to  study  the  effect  
of    oral  anti-diabetics  glimepiride, 
rosiglita-zone,  and  metformin,  on  blood  
glucose    level    in  alloxanized    diabetic  
rabbits. 
Groups 5&6: Served to study the effect of the 
fluoroquinolones  (gatifloxacin  and 
moxifloxacin) on blood glucose   level in 
control non treated rabbits. 
Group  7:  Served  to  study  the  effect  of  the 
fluoroquinolones  (gatifloxacin  and 
moxifloxacin)  on  blood  glucose  level  of 
alloxanized diabetic rabbits. 
Group 8 (insulin treated): Served to compare 
the  effect  of  the  fluoroquinolones 
(gatifloxacin and moxifloxacin) with oral 
anti-diabetics  glimepiride,  rosiglitazone, 
and metformin, on blood glucose level of 
alloxanized  diabetic  rabbits,  with  insulin 
that  was  used  as  the  standard 
hypoglycemic agent. 
 
B) Procedures and Method: 
 
1. Induction of diabetes: 
         Diabetes was induced by intraperitonial 
administration  of  alloxan  monohydrate; 
100mg/kg body weight in a doses volume of 
2ml. 2-3 successive doses, 2 days apart were 
given.  The  mentioned  procedure  produces 
type 2 diabetes in rabbits; regeneration of B 
cells  appears  within  a  month  (Katsumata  et 
al.,  1993,  Szkudelski,  2001,  Eliziane  et  al., 
2003). 
2. Collection of blood sample: 
         Blood  samples  were  taken  from  rabbit 
ear vein of fasting and postprandial animals. 
Samples  were  collected  immediately  before 
and daily after induction of diabetes.. 
         For  testing  drug  effect,  samples  were 
collected immediately before and 1, 2, 3, 4, 5, 
24, 48 hours after administration of the drug. 
For  daily  testing  of  drug  and  drug  combin-
ation effects, blood samples were collected 3 
hours after food     and drug administration. 
Blood  glucose  level  was  determined  using  a 
portable  glucose  analyzer  (Katsumata  et  al., 
1993  ,  Szkudelski,  2001).  Blood  glucose 
lowering  activity  in  rabbits  was  done 
according  to  the  method  described  by 
Gerhard Vogel (2002). 
 
Statistics: 
         Results  are  presented  as  means  ± 
standards error of means (SEM).   Statistical 
significance  was  calculated  by  one  tailed 
Student's  "t"  test.  P<  0.005  was  considered 
significant. 
 
Results 
 
1-  The  effect  of  alloxan  on  blood  glucose 
level of control non-treated rabbits: 
Blood  glucose  level  of  control  non-
treated rabbits was (4.79 ±0.26) mmol when 
measured  3  hours  after  fasting. 
Hyperglycemia  was  detected  after 
administering  alloxan  intraperitonially  in  a 
dose of  100mg/kg  body weight  repeated  2-3 
times, hypoglycemia was detected after  8-24 
hours,  doses  were  repeated  after  2  days  till 
hyperglycemia  was  detected    (Szkudelski, 
2001). There was a significant increase in the 
blood glucose level. The blood glucose levels   
were  (25.47  ±  2.52),  (21.68  ±  0.93)  and 
(19.20 ±  1.19)  mmol  on the  3  rd,  10th  and 
17th      day  post  alloxan  administration, 
respectively  (Figure  1).  The  increased  blood 
glucose levels were all significant (P < 0.05) 
compared to control non-treated rabbits. 
 
2-  The  effect  of  different  doses  of 
gatifloxacin  on  blood  glucose  level  of 
normal control   animals and  10 day  post-
alloxan administration : 
         The  effect  of  different  doses  of 
gatifloxacin  on  the  blood  glucose  level  of 
normal  animals  was  studied.  The  results 
showed  that,  gatifloxacin  when  given  daily 
for  7  successive  days  (for  the  3  animal 
groups) in the following doses 20, 40, and 80 
mg/kg/ body  weight,  it induced  a  significant 
decrease  in  blood  glucose  level  from  (4.79 
±0.26)  mmol (non-treated)  to (4.30± 0.28), 
(4.02.75  ±  0.13)  and  (3.81±  0.21)  mmol, 
respectively.    P value was < 0.05 in all the 
dose levels used (Fig.2). Hypoglycemic Effet Of Some Fluoroquinolones On…….. 
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         Gatifloxacin administration, in a dose of 
40  mg/kg  body  weight,  to  alloxan  diabetic 
animals  starting  from  the  10th  day  post-
alloxan  administration  and  for  7  successive 
days,  produced  a  little  but  significant 
hypoglycemia.  Blood  glucose  level  was 
(19.20  ±  1.19)  mmol,  while  the  alloxan 
treated  blood  glucose  level  was  (21.68  ± 
0.93)  mmol  blood  (p<0.05)  (Fig.  5), 
However,  the  combined  therapy  of 
glimepiride  (1.3  mg/kg  body  weight)  and 
gatifloxacin  (40  mg/kg/body  weight)  for  7 
successive  days  starting  from  the  10th  day 
post  alloxan  administration  produced  a 
significant  lowering  of  the  blood  glucose 
level  from  (21.68  ±  0.93)  mmol  to  (7.9  ± 
0.37) mmol blood (P<0.01) (Fig. 5).  While, 
combined therapy of metformin (80 mg / Kg 
body  weight/  day)  for  7  successive  days 
starting  from  the  10th  day  post  alloxan 
administration  produced  a  significant  and 
more  potent    effect,  from  (21.68  ±  0.93) 
mmol to (6.6± 0.36) mmol (P<0.01) (Figure 
7).  There  was  significant  lowering  of  blood 
glucose for metformin (6.6± 0.36) mmol over 
glimepiride (7.9 ± 0.37) mmol (P<0.01), with 
the mentioned drug combinations 
 
3-  The  effect  of  glimepiride  on  blood 
glucose  level  of  normal  control    (non-
treated) and alloxan diabetic rabbits: 
         Glimepiride was given orally in a dose 
of  1.3  mg/kg  body  weight  twice  daily  for  7 
successive  days  to  both  normal  and 
alloxanized  animals  starting  from  the  10th 
day  post-alloxan  injection.  The  results 
showed  significant  decrease  in  the  blood 
glucose  level  of  control  animals  from  (4.79 
±0.26) mmol to (3.65 ± 0.23) mmol blood (P 
<0.05), Also, the alloxanized animals showed 
significant decrease in the blood glucose level 
from (21.68 ± 0.93) mmol to (10.68 ± 0.69) 
mmol (P <0.05) (Figure 3).  
 
4-  The  effect  of  rosiglitazone  on  blood 
glucose  level  of  normal  control    (non-
treated) and alloxan diabetic rabbits: 
         Rosiglitazone was given orally in a dose 
of 1.3 mg/kg  body weight  once a  day for  7 
successive  days  to  both  normal  and 
alloxanized  animals  starting  from  the  10th 
day  post-alloxan  injection.  The  results 
showed  significant  decrease  in  the  blood 
glucose  level  of  control  animals  from  (4.79 
±0.26) mmol to (4.26 ± 0.22) mmol blood (P 
<0.05)  (Figure  3),  Also,  the  alloxanized 
animals  showed  significant  decrease  in  the 
blood  glucose  level  from  (21.54  ±  0.84) 
mmol  to  (13.37  ±  2.35)  mmol  (P  <0.05) 
( Figure 4).  
 
5- The effect of gatifloxacin in combination 
with glimepiride and rosiglitazone: 
on  blood  glucose  level  of  normal  control  
(non-treated)  and  the  alloxan  diabetic 
rabbits: 
         Gatifloxacin was given orally in a dose 
of  40  mg/kg  body  weight  once  a  day  for  7 
successive  days  to  both  normal  and  allox-
anized  animals  starting  from  the  10th  day 
post-alloxan  injection.  The  results  showed 
significant decrease in the blood glucose level 
of control animals from (4.79 ±0.26) mmol to 
(4.02 ± 0.13) mmol blood (P <0.05) (Fig. 2). 
Also,  the  alloxanized  animals  showed 
significant decrease in the blood glucose level 
from (21.68 ± 0.93) mmol to (19.58 ± 0.40) 
mmol blood (P <0.05) (Figure 5).  
         Gatifloxacin given in dose of 40 mg/kg 
body weight once a day plus glimepiride (1.3 
mg/  kg  body  weight  twice  a  day  for  7 
successive  days)  to  alloxanized  animals 
starting  from  the  10th  day  post-alloxan 
injection  resulted  in  significant  decrease  in 
blood  glucose  level  from  (21.68  ±  0.93) 
mmol  to  (7.90  ±  0.37)  mmol  (P  <0.01) 
(Figure 5).  
         The  previous  drug  combination  plus 
rosiglitazone (0.6 mg/ kg body weight once a 
day  for  7  successive  days)  to  alloxanized 
animals  resulted  in  significant  decrease  in 
blood  glucose  level  from  (21.68  ±  0.93) 
mmol  to  (6.42  ±  0.39)  mmol  (P  <0.01) 
(Figure 5).  
 
6-  The  effect  of  metformin  on  blood 
glucose  level  of  normal  control    (non-
treated) and the alloxan diabetic rabbits: 
         Metformin was given orally in a dose of 
80  mg/kg  body  weight  twice  a  day  for  7 
successive  days  to  both  normal  and 
alloxanized  animals  starting  from  the  10th Amr Heshmat Rostom  & Ali Ibrahim Al-Sultan   
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day  post-alloxan  injection.  The  results 
showed  significant  decrease  in  the  blood 
glucose  level  of  control  rabbits  from  (4.79 
±0.26) mmol to (3.81± 0.16) mmol (P <0.01) 
(Fig.  3).  Also,  the  alloxanized  animals 
showed  significant  decrease  in  the  blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(11.01.12± 0.57) mmol (P <0.01) (Figure 6).  
 
7- The effect of gatifloxacin in combination 
with metformin and rosiglitazone 
on  blood  glucose  level  of  normal  control  
(non-treated)  and  the  alloxan  diabetic 
rabbits:  
         Gatifloxacin (40 mg/kg b.w. once a day 
for  7  successive  days  to  both  normal  and 
alloxanized  animals)  showed  significant 
decrease in the blood glucose level of control 
animals from  (4.79 ±0.26)  mmol to  (4.02  ± 
0.13)  mmol  blood  (P  <0.05)  (Fig.  2),  Also, 
the  alloxanized  animals  showed  significant 
decrease  in  the  blood  glucose  level  from 
(21.68 ± 0.93) mmol to (19.58 ± 0.40) mmol 
blood (P <0.05) (Figure 5).  
         Gatifloxacin given in adose of 40 mg/kg 
b.w. once a day plus Metformin given in dose 
of 80 mg/kg b.w. twice a day for 7 successive 
days  to  alloxanized  animals,  resulted  in 
significant  decrease  in  blood  glucose  level 
from (21.68  ± 0.93)  mmol  to (6.60  ±  0.34) 
mmol blood (P <0.01) (Figure 7).  
         The  previous  drug  combination  plus 
rosiglitazone 0.6 mg/ kg body weight once a 
day  for  7  successive  days  to  alloxanized 
animals  resulted  in  significant  decrease  in 
blood  glucose  level  from  (21.68  ±  0.93) 
mmol  to  (4.17  ±  0.36)  mmol  (P  <0.01) 
(Figure 7).  
 
8-  Insulin  hypoglycemic  effect  in 
comparison to the effect of gatifloxacin on 
blood  glucose  level  of  normal  control  
(non-treated)  and  alloxan  diabetic  rabbits 
in  combination  with  glimepiride 
metformin and rosiglitazone: 
         Drug  doses  for  7  successive  days  to 
both normal and alloxanized animals starting 
from  the  10th  day  post-alloxan  injection 
showed  the  following:  Gatifloxacin  (40 
mg/kg b.w. once a day) resulted in significant 
decrease in the blood glucose level of control 
animals from  (4.79 ±0.26)  mmol to  (4.02  ± 
0.13)  mmol  (P  <0.05)  (Fig.  2).  Also,  the 
alloxanized  animals  showed  significant  dec-
rease in the blood glucose level from (21.68 ± 
0.93) mmol to (19.58 ± 0.40) mmol blood (P 
<0.05)  (Figure  5).  Gatifloxacin  (40  mg/kg 
b.w. once a day) plus glimepiride (1.3 mg/ kg 
b.w.  twice  a  day)  to  alloxanized  animals 
resulted  in  significant  decrease  in  blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(7.90 ± 0.37) mg/dL blood (P <0.01) (Figure 
5).    The  previous  drug  combination  plus 
rosiglitazone  (0.6  mg/  kg  b.w.  once  a  day) 
resulted  in  significant  decrease  in  blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(6.42  ±  0.39)  mmol  (P  <0.01)  (Figure  5).  
Gatifloxacin (40 mg/kg b.w. once a day) plus 
metformin  (80  mg/kg  b.w.  twice  a  day)  to 
alloxanized  animals  resulted  in  significant 
decrease in blood glucose level from (21.68 ± 
0.93) mmol to (6.60 ± 0.34) mmol (P <0.01) 
(Figure  7).    The  previous  drug  combination 
plus  rosiglitazone  (0.6  mg/  kg  b.w.  once  a 
day)  results  in  significant  decrease  in  blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(4.17  ±  0.36)  mmol  (P  <0.01)  (Figure  7). 
While  insulin  (0.5U/Kg  b.w.  a  day)  SC. 
injection  (to  alloxanized  animals  results  in 
significant  decrease  in  blood  glucose  level 
from (21.68  ± 0.93)  mmol  to (2.40  ±  0.39) 
mmol (P <0.01) (Figure 8). Hypoglycemic Effet Of Some Fluoroquinolones On…….. 
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Figure1: Effect of alloxan (100 mg / kg b.w., IP repeated twice 2 days apart) on blood glucose level 
(mmol) in control rats and after 3, 10 and 17 days of injection of alloxan. 
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Figure2:  Effect  of  different  doses  of  gatifloxacin  (20  mg,  40  mg  and  80  mg  /  kg  b.w.)  for  7 
successive days on blood glucose level (mmol) of control (non-alloxan treated) animals 
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Figure 3: Effect of glimepiride 1.3 mg/kg b.w. twice daily orally for 7 successive days on blood 
glucose level mmol) of control (non-treated) and alloxan diabetic rats (10days). Amr Heshmat Rostom  & Ali Ibrahim Al-Sultan   
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Figure 4: Effect of rosiglitazone 1.3 mg/kg b.w. a day orally for 7 successive days on blood glucose 
level (mmol) of control (non-treated) and alloxan diabetic rats (10days). 
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Figure 5: Effect of gatifloxacin (40 mg / kg b.w.) for 7 successive days on blood glucose level 
(mmol) of control (non-treated) and alloxan treated diabetic rats (10 days) and diabetic 
rats treated by glimepiride 1.3 mg/kg b.w. twice daily and rosiglitazone1.3 mg/kg b.w. 
once daily orally for 7 successive days 
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Figure 6: Effect of metformin 80 mg/kg b.w. twice a day orally for 7 successive days on blood 
glucose level (mmol) of control (non-treated) and alloxan diabetic rats (10days). 
 Hypoglycemic Effet Of Some Fluoroquinolones On…….. 
  411  
0.00
5.00
10.00
15.00
20.00
25.00
Blood 
glucose level 
mmol + SEM
1 2 3 4 5
(1) Control,(2) Alloxan,(3) Gatofloxacine+Alloxan, (4) 
Gatofloxacine+Alloxan+Metformine, (5)  
Gatofloxacine+Alloxan+Metformine+Rosiglitazone
 
Figure 7: Effect of gatifloxacin (40 mg / kg b.w. daily) for 7 successive days on blood glucose level 
(mmol) of control (non-treated) and alloxan treated diabetic rats (10 days) and diabetic 
rats treated by metformin(80 mg/Kg b.w. twice a day)  and rosiglitazone(0.6 mg/Kg 
b.w./day) orally for 7 successive days. 
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Figure  8:  Effect  of  oral  hypoglycemics  Metformin(80  mg/Kg  b.w.  twice  a  day)    and 
Rosiglitazone(0.6 mg/Kg b.w./day) orally for 7 successive days Glimepiride 1.3 mg/kg 
b.w. twice daily and Gatifloxacin (40 mg / kg b.w. daily) orally for 7 successive days 
compared to SC insulin 0.5U/Kg on blood glucose level (mmol). 
Animal groups: (1) Control (2) Alloxan   (3) Gatifloxacin  + alloxan   (4) Gatifloxacin + alloxan + 
Glimepiride        (5)  Gatifloxacin  +  alloxan  +  Glimepiride  Rosiglitazone        (6) 
Gatifloxacin  +  alloxan  +    Metformin      (7)  Gatifloxacin  +  alloxan  +  Metformin  + 
Rosiglitazone  (8) insulin 
 
Discussion 
  
         Hypoglycemic episodes in patients with 
diabetes  often  go  unrecognized,  and  over 
time,  patients  may  lose  the  ability  to  sense 
hypoglycemia, increasing their risk. Intensive 
control  of  diabetes  is  beneficial  for  patients 
with  diabetes,  but  it  increases  the  risk  of 
hypoglycemia,  underscoring  the  complexity 
of  diabetes  management  (Gabriely  and 
Shamoon , 2004). 
         Diabetes  is  largely  responsible  for 
increased  coronary  artery,  cerebrovascular 
and  peripheral  vascular  disease,  blindness, Amr Heshmat Rostom  & Ali Ibrahim Al-Sultan   
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amputations  and  end  stage  renal  disease  in 
the  developed  world.  Because  of  this,  it  is 
important  to  recognize  and  treat  this 
devastating disease early in its progression to 
postpone  or  even  prevent  the  serious 
complications  associated  with  it  (Wright  et 
al., 2006) . 
         The  combined    therapy    of    oral 
hypoglycemics  and  antimicrobials  is  a very  
common    one,    as    some    diabetics    under 
control  are  subjected  to  infection and are in 
need  for  its    administration  (Stallman  and 
Lode ,2003).  
         Hypoglycemia  is  the  limiting  factor  in 
the management of diabetes and a barrier to 
true glycemic control and becomes a progre-
ssively frequent clinical problem in advanced 
type 2 diabetes mellitus. As patients approach 
the  insulin-deficient  end  of  the  spectrum  of 
type  2,  hypoglycemia  results  from  the 
interplay  of  therapeutic  insulin  excess  and 
compromised  physiologic  and  behavioral 
defenses  against  falling  plasma  glucose 
concentrations.  By  practicing  hypoglycemia 
risk  reduction,  applying  the  principles  of 
aggressive glycemic therapy, it is possible to 
minimize  the  risk  of  hypoglycemia  and 
improve  glycemic  control.  Nonetheless, 
people  with  diabetes  need  better  treatment 
regimens (Banarer  and Cryer , 2004). 
         In  the  present  study,  diabetes  was 
induced  in  rabbits  by  alloxan  in  a  dose  of 
100mg/kg  body  weight  in  repeated  doses  to 
produce  type  2  diabetes  (Covington  et 
al.,1993),  as  rabbits  are  considered  a  good 
model  for  diabetes  mellitus  (Gerhard  Vogel, 
2002). 
         The  blood  glucose  level  was  estimated 
by  the  procedure  of  Gruppuso  et  al,(1990) 
which  is  a  chemical  method.        It  has  the 
advantage  over  other  methods  that  it  can 
estimate  the  blood    glucose    in    the    whole  
blood  with  the  avoidance of  the  problem  
of    haemolysis    which    is  usually    encou-
ntered  with    the    animals    blood    sampling  
(Gruppuso et  al., 1990) 
         Blood  glucose  level  of  control  non-
treated rabbits was (4.79 ±0.26) mmol. After 
alloxan administration there was a significant 
increase  in  the  blood  glucose  to  (25.47  ± 
2.52), (21.68 ± 0.93) and (19.20 ± 1.19) on 
the  3  rd,  10th  and  17th      day  respectively 
(Figure 1). The increased blood glucose level 
was  significant  with  all  measurements  (P  < 
0.05). The action of alloxan on the pancreas 
is preceded by its rapid uptake by the B cells 
(Boquist  et  al.,  1983).  Rapid  uptake  by 
insulin-secreting cells  has  been  proposed  to 
be  one  of  the  important features  determining 
alloxan  diabetogenicity.  Another aspect 
concerns the formation of reactive oxygen. A 
similar uptake  of alloxan  also takes place  in 
the liver. However, the liver and other tissues 
are more resistant to reactive oxygen species 
in comparison  to  pancreatic  B  cells  and  this 
resistance  protects  them  against  alloxan 
toxicity  (Tiedge  et  al.,  1997  ;  Szkudelski, 
2001)  
         Glimepiride  blocks  both  B-cells  and 
cardiac  cloned  KATP  channels  with  high 
affinity,  since  KATP channels  are  found  in  a 
wide  variety  of  extra  pancreatic  tissues 
(cardiac, skeletal muscle, smooth muscle and 
neurons)  and  benzamido-binding  site  (SUE1 
and  SUR2A),  these  might  have  greater 
therapeutic  value  in  type  II  diabetes  than 
sulfonylureas  that  interact  with  SUR1  only 
e.g.  tolbutamide  (Frances  and  Fiona,  2000). 
Glimepiride  administration  in  a  dose  of  l.3 
mg/kg. body weight  orally  twice  daily  for  
7  successive  days from  the  10
th  day post-
alloxan    injection,  induced  a  significant  
decrease  in  the  hyperglycemic  state  from 
(21.68+  0.93)  to  (10.68  +  0.69)  mmol  (P 
0.01), although, it causes about 50% decrease 
in blood glucose level, it still not enough for 
the desired control of blood glucose. In non-
alloxan  treated  animals,  blood  glucose  level 
was also decreased from (4.79+ 0.26) to (3.65 
+  0.23)  mmol,  (P  0.01)  (Figure  3)  for  the 
same  effect  on  pancreatic  and  extra 
pancreatic tissues. 
         Fluoroquinolones are used widely in the 
treatment of various infectious diseases; some 
of  the  drugs  are  known  to  cause  hypogl-
ycemia as  a side-effect.  The effects  of  three 
fluoroquinolone  derivatives,  levoflo-xacin, 
gatifloxacin,  and  temafloxacin  on  insulin 
secretion  and  pancreatic  beta-cell  ATP-
sensitive K(+) channel it was found that they 
ininhibit the  K(ATP) channel activity. While 
levofloxacin  had  only  a  small  effect  on Hypoglycemic Effet Of Some Fluoroquinolones On…….. 
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insulin  secretion  and  K  (ATP)  currents, 
gatifloxacin  and  temafloxacin  stimulated 
insulin  secretion  and  inhibited  K  (ATP) 
channel currents in a dose-dependent manner. 
The  site  of  action  of  gatifloxacin  and 
temafloxacin  on  the  K  (ATP)  channel  was 
determined.  In  a  reconstituted  system, 
gatifloxacin  and  temafloxacin  inhibited 
Kir6.2 Delta C26 channels, which function in 
the  absence  of  the  SUR  subunit,  indicating 
direct  action  of  the  drugs  on  the  Kir6.2 
subunits.  These  results  suggest  that 
stimulation  of  insulin  secretion  by  inhibition 
of  pancreatic  beta-cell  K  (ATP)  channels 
underlies the hypoglycemia caused by certain 
fluoroquinolones (Saraya et al., 2004). 
         Gatifloxacin  and  Moxifloxacin  when 
given  daily  for  7  successive  days  in  the 
following doses 20, 40, and 80 mg/kg/ body 
weight, they induced a significant decrease in 
blood glucose level from (4.79 ±0.26) mmol 
to (4.30± 0.28), (4.02.75 ± 0.13) and (3.81± 
0.21) mmol blood respectively.   P value was 
<  0.05  in  all  the  dose  levels  of  the  used 
antibiotics (Fig.2). 
         Gatifloxacin and moxifloxacin adminis-
tration  produced  a  little  but  significant 
hypoglycemia.  Blood  glucose  level  was 
(19.20 ± 1.19) mmol while the alloxan treated 
blood glucose level was (21.68 ± 0.93) mmol 
(p<0.05)  (Fig.  5),  However,  the  combined 
therapy  of  glimepiride  and  gatifloxacin 
produced a significant lowering of the blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(7.9  ±  0.37)  mmol  (P<0.01)  (Figure  5).  
While,  glimepiride  combined  therapy  with 
metformin  produced  a  significant  and  more 
potent    lowering  of  the  blood  glucose  level  
from  (21.68  ±  0.93)  mmol  blood  to  (6.6± 
0.36)  mmol  blood  (P<0.01)  (Figure  7).  The 
hypoglycemic  effect  of  metformin  was  more 
potent  than  that  of  glimepiride  with  the 
mentioned  drug  doses  in  the  mentioned 
combinations (see Fig. 7). 
         The incidence of specific adverse events 
associated  with  individual  fluoroquinolones 
was  reviewed  in  a  five-year  post-marketing 
surveillance (PMS) study in Japan, in which a 
total  adverse  drug  reaction  (ADR)  rate  of 
1.3%  was  found  for  levofloxacin,  compared 
to total ADR rates of 3.3% for pazufloxacin, 
3.6% for tosufloxacin, 4.5% for gatifloxacin 
and 5.4% for balofloxacin. Levofloxacin had 
the  lowest  rate  of  CNS  effects  and  skin 
adverse  effects  among  the  agents  studded. 
(Rubinstein, 2001) 
         The  hypoglycemic  effect  of  rosiglit-
azone given in dose used to both normal and 
alloxanized  animals  resulted  in  significant 
decrease in the blood glucose level of control 
animals from  (4.79 ±0.26)  mmol to  (4.26  ± 
0.22)  mmol  (P  <0.05)  (Table  3),  Also,  the 
alloxanized  animals  showed  significant  dec-
rease in the blood glucose level from (21.54 ± 
0.84) mmol to (13.37 ± 2.35) mmol (P <0.05) 
(Figure 4).  
         Rosiglitazone  is  a  pure  ligand  of  
PPARγ, and has no PPARʱ- binding action. 
Apart from its effect on insulin resistance , it 
appears  to  have  an  anti-inflammatory  effect 
(Mohandy et al., 2004). The nuclear receptor 
family of PPARs was named for the ability of 
the  original  member  to  induce  hepatic 
peroxisome proliferation  in mice  in  response 
to xenobiotic stimuli. However, studies on the 
action  and  structure  of  the  3  human  PPAR 
isotypes  (PPARʱ,  PPARʴ,  and  PPARγ) 
suggest  that  these  moieties  are  intimately 
involved  in  nutrient  sensing  and  the 
regulation of carbohydrate and lipid metabo-
lism. PPARʱ and PPARʴ appear primarily to 
stimulate  oxidative  lipid  metabolism,  while 
PPARγ is principally involved in the cellular 
assimilation  of  lipids  via  anabolic  pathways 
Robert et al., (2006).  
         Metformin  produced  significant 
decrease in the blood glucose level of control 
rabbits  from  (4.79  ±0.26)  mmol  to  (3.81± 
0.16)  mmol  blood  (P  <0.01)  (Fig.  3),  Also, 
the  alloxanized  animals  showed  significant 
decrease  in  the  blood  glucose  level  from 
(21.68  ±  0.93)  mmol  to  (11.01.12±  0.57) 
mmol blood (P <0.01) (Figure 6).  
         AMP-activated protein kinase (AMPK) 
is  an  enzyme  that  works  as  a  fuel  gauge 
which  becomes  activated  in  situations  of 
energy  consumption.  AMPK  is  involved  in 
the  mechanism  of  action  of  metformin  and 
thiozolidinediones,  and  the  adipocytokines 
leptin and adiponectin. These data, along with 
evidence  that  pharmacological  activation  of 
AMPK  in  vivo  improves  blood  glucose Amr Heshmat Rostom  & Ali Ibrahim Al-Sultan   
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homeostasis, (Schimmack et al., 2006). AMP 
kinase  pathway  activation  by  metformin, 
recently shown to be necessary for metformin 
inhibition  of  gluconeogenesis  in  hepatocytes, 
is also involved in metformin-induced growth 
inhibition  of  epithelial  cells.  The  growth 
inhibition  was  associated  with  decreased 
mammalian  target  of  rapamycin  and  S6 
kinase  activation  and  a  general  decrease  in 
mRNA  translation.  These  results  provide 
evidence  for  a  mechanism  that  may  contr-
ibute  to  the  antineoplastic  effects  of  Metfo-
rmin suggested by (Zakikhani et al., 2006).  
         Metformin plus gatifloxacin given for 7 
successive  days  to  alloxanized  animals 
resulted  in  significant  decrease  in  blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(6.60 ± 0.34) mmol (P <0.01) (Figure 7). The 
previous drug combination plus rosiglitazone 
resulted  in  significant  decrease  in  blood 
glucose  level  from  (21.68  ±  0.93)  mmol  to 
(4.17 ± 0.36) mmol (P <0.01) (Figure 7).  
         Garber  et  al.,  (2006)  showed  that 
metformin-glibenclamide  tablets  resulted  in 
significantly greater  reductions  in  HbA1C  (-
1.5%)  and  fasting  plasma  glucose  [-2.6 
mmol/l  (-46  mg/dl)]  than  metformin  plus 
rosiglitazone [-1.1%, p < 0.001; -2 mmol/l (-
36 mg/dl), p = 0.03]. More patients receiving 
metformin-glibenclamide  attained  HbA1C 
<7.0% than  did  those in  the  metformin  plus 
rosiglitazone  group  (60  vs.  47%)  and  had 
fasting  plasma  glucose  levels  <7  mmol/l 
(<126  mg/dl)  by  week  24  (34  vs.  25%) 
(Garber et al., 2006) 
         Insulin  (0.5U/Kg  b.w.  a  day)  SC. 
injection  (to  alloxanized  animals  resulted  in 
significant  decrease  in  blood  glucose  level 
from (21.68  ± 0.93)  mmol  to (2.40  ±  0.39) 
mmol (P <0.01) (Figure 8). 
         The  results  may  also  be  explained  by 
the  study  of  Bruce  et  al.,  (2006)  that 
evaluated  the  mechanism  of  action  of 
metformin-glibenclamide  combination  tablets 
(Glucovance)  vs.  metformin  and  glibencl-
amide  in  50  type  2  diabetes  patients 
inadequately controlled  by  diet  and  exercise. 
A  glycaemic  target  of  HbA1C  7.0%  was 
used.  Final  HbA(1C),  fasting  glucose  and 
post-oral  glucose  tolerance  test  (OGTT) 
blood  glucose  levels  were  similar  between 
groups, although average doses of metformin 
and  glibenclamide  from  combination  tablets 
(708  and  3.5  mg)  were  lower  than 
monotherapy  doses  (1500  and  6.6  mg). 
Second-phase  insulin  during  a  hypergly-
caemic  clamp  increased  by  93%  with 
combination tablets, 36% with metformin and 
46%  with  glibenclamide.  The  insulin 
response post- oral glucose tolerance test was 
more  rapid  with  the  combination  tablets  vs. 
glibenclamide.  First-phase  insulin  responses 
improved  modestly  in  all  groups,  possibly 
due  to  reduced  glucotoxicity.  Changes  in 
insulin  sensitivity  were  minor.  Larger  beta-
cell  responses  between  combination  tablets 
and  glibenclamide  may  reflect  more  rapid 
glibenclamide absorption. 
 
Conclusion 
 
         As  hypoglycemia  is  the  limiting  factor 
in the glycemic management of diabetes  and 
a  barrier  to  true  glycemic  control,  frequent 
clinical problems in advanced type 2 diabetes 
mellitus  are  progressively  encountered. 
Hypoglycemia  results  from  the  interplay  of 
therapeutic  agents.  By  practicing  hypogly-
cemia risk  reduction, applying  the  principles 
of  aggressive  glycemic  therapy,  and  consid-
ering  conventional  risk  factors  and  those 
indicative of compromised glucose counterre-
gulation, it is possible to minimize the risk of 
hypoglycemia and  improve glycemic  control. 
Nonetheless, people with diabetes need better 
treatment regimens. The present study shows 
that  gatifloxacin  and  moxifloxacin  lower 
blood  glucose  level  in  healthy  and  alloxan 
induced  diabetic  rabbits.  Also,  these  drugs 
augment the blood glucose lowering effect of 
glimeperide,  rosiglitazone,  and  metformin. 
The  drug  combinations  had  synergistic 
hypoglycemic  effect  that  was  potentiated  by 
gatifloxacin and moxifloxacin 
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زوولوىيكورولفلا ريثأج هم مدلا يف ركسلا ضافخوا  
ىركسلاب ةباصملا و ةيعيبطلا براجحلا تاواويح يف  
 
ثمشح دمحا ورمع *   -   لع  ناطلسلا ي **  
 ىسل   ٗجٕنٕكايرافنا *     -      ةُٛغاثنا ضازيلاا **  
 ةطنا ةٛهك –    ءاسحلاا مصٛف كهًنا ةعياج  
 
           جلاعن عسأ قاطَ ٗهع وذخحسج ٙحنا ةٕٚٛحنا تاداعًنا ٍي شَٕنُٕٛكٔرٕهفنا تاثكزي
تاٛفشحسًنا ٗف ّثسحكًنا ضازيلأأ عًحجًنا ضازيا  . زيلاا اذْ عٕٛش وذع ىغرٔ  , لاإ    َّا
تلااحنا  طعت  ٗف  وذنا  ٗف  زكسنا  ةثسَ  ٗف  ضافخَا  خٔذح  ظحٕن  ,  طعت  تدرٔ  اًك
 زٚرامحنا ,  ٗظزًنا ٙف ٌاٛحلاا ةهغا ٙف خذحٚ َّا ٔذثٚٔ شَٕنُٕٛكٔرٕهفنا تاثكزي لاًعحسا عي
 ًٗفنا جلاعنا ٌٕمهحٚ ٍٚذنأ َٗاثنا عُٕنا ٍي ٘زكسنا ضزي عي ٍُٛسًنا ( صازللاا  .)  زٛشج
ّٚزٚزسنا تاَاٛثنا    كٚزطت سٕكٕهجنا ٌسإج ٗهع زثؤج ٌا ٍكًٚ شَٕنُٕٛكٔرٕهفنا تاثكزي ٌا ٗنا
ذعت  فٔزعي  زٛغ  .  تاثكزي  طعثن  ةهًححًنا  راثٜا  فاشكحسا  ٗنا  فذٓٚ  مًعنا  اذْ
براجحنا تاَإٛح ٙف سٕكٕهجنا ٖٕحسئ وذنات سٕكٕهجنا طٚا ٗهع شَٕنُٕٛكٔرٕهفنا  .  ذل ٔ
كٔرٕهفنا تاثكزي ٍي ٍُٛثا ٍٛعَٕ وذخحسا  ٍٛساسكٕهفٛسكٕي ٔ ٍٛساسكٕهفٛحٛجنا أًْ شَٕنُٕٛ
 مكشت ٘زكسنات ةتاصئ ةٛعٛثغ ؛ ةَرلاا ٍي ةفهحخي تاعًٕجي واذخحسات ّسارذنا ِذْ ٙف
ٙثٚزجج  . اُفذْا ىْا ٍي ثَاك ةيلاسنا تاراثحعإ .  
           ٍمح ىج ، مًعنا اذْ ٙف 011    ٗف ىسجنا ٌسٔ ٍي وازجٕهٛك مكن ٌاسكٕنلاا ٍي وازجٛههي
3   براجحنا تاَإٛح ٙف ٘زكسنا ضزي خاذحلإ ٌٕحٚزثنا ٗف ، ةٛناححي تاعزج  .  ّساٛل ىج
ٌاسكٕنلاا  ذعت  براجحنا  تاَإٛح  ءايد  ٗف  سٕكٕهجنا  ٖٕحسي .  ًٗفنا  جلاعنا  واذخحسا  عي
( صازللاا  )  ثجحَاذل ٔ ٍٛيرٕفحًٛنا ٔ ٌٔساحٛهجٚسٔزنا ٔ ذٚزثًٛٛهجنا ْٗ ٔ ٘زكسنا ةحفاكًن
ٗهع زثلاا زٛثك طٛفخج   ٘زكسنات ةتاصًنأ ةٛعٛثطنا تاَإٛحنا ود ٙف سٕكٕهجنا ٖٕحسي .  اًك
 ٗف وذنا ٙف سٕكٕهجنا ٖٕحسي ٗف مثاًي اظافخَا ٍٛساسكٕهفٛسكٕي ٔ ٍٛساسكٕهفٛحٛجنا خذحا
 براجحنا تاَإٛح (  ةَارلاا  )  ةٕٚمجٔ ٗئاصحا ضافخَا خذح اًك ٘زكسنات ةتاصئ ةٛعٛثغ
  ًٗفنا  جلاعنا  ةٛهعاف ( صازللاا  ) فاكًن  ةَارلااىف  شَٕنُٕٛكٔرٕهفنا  تاثكزي  عي  ٘زكسنا  ةح
٘زكسنات ةتاصًنأ ةٛعٛثطنا .  
 
 
 
 
 
 